Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 4/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9177398 | 0.82 | CYP2D6 (0.42) | ARG1ARG2S1PR1S1PR5ALDH1A1 | |
| SCHEMBL17512704 | 0.80 | S1PR1 (0.43) | S1PR1S1PR5 | |
| SCHEMBL9838655 | 0.80 | ALDH1A1 (0.42) | S1PR1S1PR5ALDH1A1 | |
| SCHEMBL9185202 | 0.78 | KMT2A (0.46) | ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL9182347 | 0.77 | KMT2A (0.45) | ALDH1A1 | |
| SCHEMBL4683643 | 0.77 | CHRM3 (0.40) | CHRM3CHRM2CHRM1NR1I2RORC | |
| SCHEMBL3909542 | 0.77 | CHRM3 (0.40) | CHRM3CHRM2CHRM1NR1I2RORC | |
| SCHEMBL5948243 | 0.76 | CHRM2 (0.48) | CHRM3CHRM2CHRM1ALDH1A1 | |
| SCHEMBL5948242 | 0.76 | CHRM2 (0.48) | CHRM3CHRM2CHRM1ALDH1A1 | |
| SCHEMBL9185084 | 0.76 | CTSK (0.40) | S1PR1S1PR5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592359-B2 | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-22 | — | — | US | claimed |
| US-20070287732-A1 | Substituted Azabicyclo Hexane Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-12-13 | — | — | US | claimed |
| EP-1615634-B1 | SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2007-05-16 | — | — | EP | claimed |
| US-7592359-B2 | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-22 | — | — | US | disclosed |
| US-20070287732-A1 | Substituted Azabicyclo Hexane Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-12-13 | — | — | US | disclosed |
| EP-1615634-B1 | SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2007-05-16 | — | — | EP | disclosed |
| EP-1615634-A1 | SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089363-A1 | SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287732-A1 | Substituted Azabicyclo Hexane Derivatives as Muscarinic Receptor Antagonists | CHRM5, CHRM3, CHRM2 | CHRM3 2/4885CHRM2 3/4885CHRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.